HCW Stock Based Compensation To Revenue from 2010 to 2024
| HCWB Stock | USD 0.56 0.05 8.20% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.35320963 | Current Value 0.37 | Quarterly Volatility 0.1294495 |
Check HCW Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HCW Biologics' main balance sheet or income statement drivers, such as Interest Income of 610.2 K, Depreciation And Amortization of 717.9 K or Interest Expense of 201.3 K, as well as many indicators such as Price To Sales Ratio of 30.12, Dividend Yield of 0.0272 or PTB Ratio of 3.12. HCW financial statements analysis is a perfect complement when working with HCW Biologics Valuation or Volatility modules.
HCW | Stock Based Compensation To Revenue |
Latest HCW Biologics' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of HCW Biologics over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. HCW Biologics' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HCW Biologics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
HCW Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.07 | |
| Geometric Mean | 0.01 | |
| Coefficient Of Variation | 174.12 | |
| Mean Deviation | 0.10 | |
| Median | 0.01 | |
| Standard Deviation | 0.13 | |
| Sample Variance | 0.02 | |
| Range | 0.3647 | |
| R-Value | 0.75 | |
| Mean Square Error | 0.01 | |
| R-Squared | 0.56 | |
| Significance | 0 | |
| Slope | 0.02 | |
| Total Sum of Squares | 0.23 |
HCW Stock Based Compensation To Revenue History
About HCW Biologics Financial Statements
HCW Biologics stakeholders use historical fundamental indicators, such as HCW Biologics' Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although HCW Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in HCW Biologics' assets and liabilities are reflected in the revenues and expenses on HCW Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in HCW Biologics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.35 | 0.37 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out the analysis of HCW Biologics Correlation against competitors. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.